|
1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the surveillance, epidemiology, and end results program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar
|
|
3
|
Broadhead ML, Clark JC, Myers DE, Dass CR
and Choong PF: The molecular pathogenesis of osteosarcoma: A
review. Sarcoma. 2011:9592482011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kansara M, Teng MW, Smyth MJ and Thomas
DM: Translational biology of osteosarcoma. Nat Rev Cancer.
14:722–735. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Di Fiore R, Drago-Ferrante R, Pentimalli
F, Di Marzo D, Forte IM, D'Anneo A, Carlisi D, De Blasio A,
Giuliano M, Tesoriere G, et al: MicroRNA-29b-1 impairs in vitro
cell proliferation, self-renewal and chemoresistance of human
osteosarcoma 3AB-OS cancer stem cells. Int J Oncol. 45:2013–2023.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Durfee RA, Mohammed M and Luu HH: Review
of osteosarcoma and current management. Rheumatol Ther. 3:221–243.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xie B, Ding Q, Han H and Wu D: miRCancer:
A microRNA-cancer association database constructed by text mining
on literature. Bioinformatics. 29:638–644. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dinh TK, Fendler W, Chałubińska-Fendler J,
Acharya SS, O'Leary C, Deraska PV, D'Andrea AD, Chowdhury D and
Kozono D: Circulating miR-29a and miR-150 correlate with delivered
dose during thoracic radiation therapy for non-small cell lung
cancer. Radiat Oncol. 11:612016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pasqualini L, Bu H, Puhr M, Narisu N,
Rainer J, Schlick B, Schäfer G, Angelova M, Trajanoski Z, Börno ST,
et al: miR-22 and miR-29a are members of the androgen receptor
cistrome modulating LAMC1 and Mcl-1 in prostate cancer. Mol
Endocrinol. 29:1037–1054. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang H, Bai M, Deng T, Liu R, Wang X, Qu
Y, Duan J, Zhang L, Ning T, Ge S, et al: Cell-derived microvesicles
mediate the delivery of miR-29a/c to suppress angiogenesis in
gastric carcinoma. Cancer Lett. 375:331–339. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sampson VB, Yoo S, Kumar A, Vetter NS and
Kolb EA: MicroRNAs and potential targets in osteosarcoma: Review.
Front Pediatr. 3:692015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He DX, Gu XT, Li YR, Jiang L, Jin J and Ma
X: Methylation- regulated miR-149 modulates chemoresistance by
targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast
cancer. FEBS J. 281:4718–4730. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li X, Pan Q, Wan X, Mao Y, Lu W, Xie X and
Cheng X: Methylation-associated Has-miR-9 deregulation in
paclitaxel- resistant epithelial ovarian carcinoma. BMC Cancer.
15:5092015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu YL, Lensing SY, Yan Y, Webster C and
Emanuel PD: Overexpression Of DNMT3a and DNMT3b is related to
down-regulation of Mir-29a in juvenile myelomonocytic leukemia
(JMML). Blood. 122:48902013.
|
|
16
|
Babon JJ and Nicola NA: The biology and
mechanism of action of suppressor of cytokine signaling 3. Growth
Factors. 30:207–219. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Beaurivage C, Champagne A, Tobelaim WS,
Pomerleau V, Menendez A and Saucier C: SOCS1 in cancer: An oncogene
and a tumor suppressor. Cytokine. 82:87–94. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang XH, Yang L, Liu XJ, Zhan Y, Pan YX,
Wang XZ and Luo JM: Association between methylation of tumor
suppressor gene SOCS1 and acute myeloid leukemia. Oncol Rep.
40:1008–1016. 2018.PubMed/NCBI
|
|
19
|
Huang FJ, Steeg P, Price J, Sawaya R and
Huang S: Suppressor of cytokine signaling-1 (SOCS-1) negatively
regulates angiogenesis, invasion, and brain metastasis of melanoma
cells. Cancer Res. 68:2008. View Article : Google Scholar
|
|
20
|
Shao N, Ma G, Zhang J and Zhu W:
miR-221-5p enhances cell proliferation and metastasis through
post-transcriptional regulation of SOCS1 in human prostate cancer.
BMC Urol. 18:142018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hashimoto M, Ayada T, Kinjyo I, Hiwatashi
K, Yoshida H, Okada Y, Kobayashi T and Yoshimura A: Silencing of
SOCS1 in macrophages suppresses tumor development by enhancing
antitumor inflammation. Cancer Sci. 100:730–736. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gaspericampani A, Pancotti F and Roncuzzi
L: Abstract 4396: Caveolin-1 as an oncopromoter in solidtumors: A
role mediated by STAT3 in vitro. Cancer Res. 73(8 Suppl): S4396.
2014.
|
|
23
|
Zhang H, Zhao Z, Pang X, Yang J, Yu H,
Zhang Y, Zhou H and Zhao J: Genistein protects against
Ox-LDL-induced inflammation through microRNA-155/SOCS1-mediated
repression of NF-ĸB signaling pathway in HUVECs. Inflammation.
40:1450–1459. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee YJ, Han JY, Byun J, Park HJ, Park EM,
Chong YH, Cho MS and Kang JL: Inhibiting Mer receptor tyrosine
kinase suppresses STAT1, SOCS1/3, and NF-κB activation and enhances
inflammatory responses in lipopolysaccharide-induced acute lung
injury. J Leukoc Biol. 91:921–932. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ren D, Yang Q, Dai Y, Guo W, Du H, Song L
and Peng X: Oncogenic miR-210-3p promotes prostate cancer cell EMT
and bone metastasis via NF-κB signaling pathway. Mol Cancer.
16:1172017. View Article : Google Scholar
|
|
26
|
Liu X, Li J, Peng X, Lv B, Wang P, Zhao X
and Yu B: Geraniin inhibits LPS-induced THP-1 macrophages switching
to M1 phenotype via SOCS1/NF-κB pathway. Inflammation.
39:1421–1433. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Maier HJ, Schmidt-Strassburger U, Huber
MA, Wiedemann EM, Beug H and Wirth T: NF-kappaB promotes
epithelial-mesenchymal transition, migration and invasion of
pancreatic carcinoma cells. Cancer Lett. 295:214–228. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu Y and Zhou BP:
TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and
invasion. Br J Cancer. 102:639–644. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Meister P, Konrad E, Lob G, Janka G, Keyl
W and Stürz H: Osteosarcoma: Histological evaluation and grading.
Arch Orthop Trauma Surg. 94:91–98. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
31
|
Brunet Vega A, Pericay C, Moya I, Ferrer
A, Dotor E, Pisa A, Casalots A, Serra-Aracil X, Oliva JC, Ruiz A
and Saigí E: microRNA expression profile in stage III colorectal
cancer: Circulating miR-18a and miR-29a as promising biomarkers.
Oncol Rep. 30:320–326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang W, Qian JX, Yi HL, Yang ZD, Wang CF,
Chen JY, Wei XZ, Fu Q and Ma H: The microRNA-29 plays a central
role in osteosarcoma pathogenesis and progression. Mol Biol (Mosk).
46:622–627. 2012. View Article : Google Scholar
|
|
33
|
Lv Y, Song G and Li P: Correlation of
SOCS-1 gene with onset and prognosis of breast cancer. Oncol Lett.
16:383–387. 2018.PubMed/NCBI
|
|
34
|
Wang X, Liu S, Cao L, Zhang T, Yue D, Wang
L, Ping Y, He Q, Zhang C, Wang M, et al: miR-29a-3p suppresses cell
proliferation and migration by downregulating IGF1R in
hepatocellular carcinoma. Oncotarget. 8:86592–86603.
2017.PubMed/NCBI
|
|
35
|
Qin S, Ai F, Ji WF, Rao W, Zhang HC and
Yao WJ: miR-19a promotes cell growth and tumorigenesis through
targeting SOCS1 in gastric cancer. Asian Pac J Cancer Prev.
14:835–840. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Agarwal S, Amin KS, Jagadeesh S, Baishay
G, Rao PG, Barua NC, Bhattacharya S and Banerjee PP: Mahanine
restores RASSF1A expression by down-regulating DNMT1 and DNMT3B in
prostate cancer cells. Mol Cancer. 12:992013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen Q, Dan Y, Zhang Y, Yu L, Li XD, Zhou
ZJ, Zhou SL, Gao DM, Hu J, Jin C, et al: MicroRNA-29a induces loss
of 5-hydroxymethylcytosine and promotes metastasis of
hepatocellular carcinoma through a TET-SOCS1-MMP9 signaling axis.
Cell Death Dis. 8:e29062017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Maugeri M, Barbagallo D, Barbagallo C,
Banelli B, Di Mauro S, Purrello F, Magro G, Ragusa M, Di Pietro C,
Romani M and Purrello M: Altered expression of miRNAs and
methylation of their promoters are correlated in neuroblastoma.
Oncotarget. 7:83330–83341. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fu X, Song X, Li Y, Tan D and Liu G:
Hepatitis B virus X protein upregulates DNA methyltransferase 3A/3B
and enhances SOCS-1CpG island methylation. Mol Med Rep. 13:301–308.
2016. View Article : Google Scholar
|
|
40
|
Gebeshuber CA, Zatloukal K and Martinez J:
miR-29a suppresses tristetraprolin, which is a regulator of
epithelial polarity and metastasis. EMBO Rep. 10:400–405. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kogure T, Kondo Y, Kakazu E, Ninomiya M,
Kimura O and Shimosegawa T: Involvement of miRNA-29a in epigenetic
regulation of transforming growth factor-β-induced
epithelial-mesenchymal transition in hepatocellular carcinoma.
Hepatol Res. 44:907–919. 2014. View Article : Google Scholar
|
|
42
|
Tang B, Li X, Ren Y, Wang J, Xu D, Hang Y,
Zhou T, Li F and Wang L: MicroRNA-29a regulates lipopolysaccharide
(LPS)-induced inflammatory responses in murine macrophages through
the Akt1/NF-κB pathway. Exp Cell Res. 360:74–80. 2017. View Article : Google Scholar : PubMed/NCBI
|
